$Cognition Therapeutics (CGTX.US)$ Cognition Therapeutics, I...

$Cognition Therapeutics (CGTX.US)$ Cognition Therapeutics, Inc. (nasdaq: CGTX) is a clinical-stage company dedicated to developing drugs for the treatment of neurodegenerative diseases, providing an update on the biomarker analysis in the phase 2 'SHINE' study in mild to moderate Alzheimer's disease. This new analysis focuses on plasma samples from all participants entering the study with low levels of plasma P-t217. Several blood-based measurements of Alzheimer's disease biology were normalized in the CT1812 treatment group compared to the placebo group. These biomarker changes are consistent with a 95% slowing in cognitive decline measured by ADAS-Cog11 in the same patients. These data further demonstrate that CT1812 may maintain cognitive function and slow disease progression by protecting critical neural systems.